Life Sciences Alternative Funding

Harrow Health, Inc. is a pharmaceutical company based in San Diego, California, specializing in the development, production, and sale of innovative ophthalmic medications primarily for the U.S. market. The company focuses on addressing unmet medical needs in eye care by providing a range of prescription and non-prescription products. Its portfolio includes specialized formulations such as topical eye drops, oral capsules for ocular surface diseases, and therapeutics for sedation in medical procedures. Notable products include SURF-100, SURF-200, and MELT-100, among others. Additionally, Harrow Health is engaged in developing treatments for rare conditions, such as interstitial cystitis. Founded in 1998 and previously known as Imprimis Pharmaceuticals, the company aims to make its medications accessible and affordable for both healthcare professionals and patients.

VENITI is the first medical device company developing a suite of innovative technology and solutions that will provide comprehensive treatment across the venous disease continuum. Venous disease refers to all conditions related to or caused by veins that become diseased or abnormal. This encompasses a broad set of maladies. The venous disease cycle begins when vein walls become weak or damaged, or the valves are stretched or injured, and can no longer prevent reflux (backward flow of blood). Once the veins lose their ability to convey blood without reflux, the progressive venous disease cycle has begun. This is commonly referred to as chronic venous insufficiency, or CVI. The blood will begin to back up into the peripheral veins, causing venous hypertension, potential thrombosis (clotting), and leading to even more damage of the vein walls and valves. This in turn leads to more reflux. The VENITI team of experts in science, technology and business are currently developing the VENITI VICI VENOUS STENT® System. Through this, and other, innovative technology, VENITI will achieve results that sets it apart in addressing the challenges specific to the venous system and venous disease.

Integrated Diagnostics Inc. specializes in the development of laboratory-based blood molecular diagnostic tools designed to assist physicians in the early detection of complex diseases through non-invasive blood tests. The company's flagship product, Xpresys Lung, provides objective information for assessing pulmonary nodules by monitoring multiple disease molecular markers simultaneously. Founded in 2005 and based in Seattle, Washington, Integrated Diagnostics aims to leverage emerging technologies to create a pipeline of innovative diagnostic products that facilitate the management of serious conditions such as cancer, diabetes, and Alzheimer's. The company operates under the principle that a systems view of disease, involving networks of proteins, genes, and other molecules, is essential for effective diagnosis and prognosis. Integrated Diagnostics is a subsidiary of Biodesix, Inc. and has established a strategic partnership with Agilent Technologies.

VisionCare Ophthalmic Technologies, Inc. is a specialty medical device company based in Saratoga, California, focused on the research, development, manufacture, and marketing of innovative implantable ophthalmic devices. The company primarily aims to enhance vision and quality of life for individuals suffering from untreatable retinal disorders, particularly end-stage age-related macular degeneration (AMD), which is a leading cause of blindness among older Americans. VisionCare's flagship product is the Implantable Miniature Telescope, the first FDA-approved device designed to improve vision in patients with advanced AMD. This telescope implant is a critical component of the CentraSight treatment program, which guides patients through the processes of diagnosis, surgical evaluation, and postoperative care. Founded in 1997, VisionCare is dedicated to helping patients reconnect with their daily lives and activities through its advanced visual prosthetic technologies.